Novel ELISA for serodiagnosis of nasopharyngeal carcinoma based on a B cell epitope of Epstein-Barr virus latent membrane protein 2

doi:10.3892/ol.2018.9216

科研成果详情

题名	Novel ELISA for serodiagnosis of nasopharyngeal carcinoma based on a B cell epitope of Epstein-Barr virus latent membrane protein 2
作者	Cai, Yiqi1; Song, Yiling 2; Cen, Danwei 2; Zhang, Chanqiong 2; Mao, Shanshan 2; Ye, Xiaoxian2; Xiong, Yirong 2; Jiang, Pengfei2; Chen, Jun2; Xue, Xiangyang2; Zhang, Lifang2; Zhu, Guanbao1
发表日期	2018-10
发表期刊	ONCOLOGY LETTERS 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Epstein-Barr virus epitope latent membrane protein 2 nasopharyngeal carcinoma serological diagnosis
其他关键词	INFECTION ; DIAGNOSIS ; PATHOGENESIS ; ANTIBODIES ; LYMPHOMA ; LMP2 ; NPC
摘要	Epstein-Barr virus (EBV) is widespread and is associated with nasopharyngeal carcinoma (NPC). Serological detection of EBV is commonly used for screening, diagnosis and epidemiological surveys of NPC. In the present study, a novel B cell multi-epitope peptide fusion protein (EBV-LMP2-3B), which is composed of three B cell linear epitopes (RIEDPPFNSLL, TLNLT and KSLSSTEFIPN) of EBV latent membrane protein 2 (LMP2), was expressed in a prokaryotic expression system and purified using Ni2+-nitrilotriacetate-Sepharose. The immunogenicity and binding specificity of EBV-LMP2-3B were evaluated on the basis of antibody responses in immunized BALB/c mice, western blotting and indirect immunofluorescence assay. Evaluation of EBV-LMP2-3B as a serological diagnostic reagent was performed using an indirect ELISA in 198 patients with NPC and 102 healthy adults. These results revealed that EBV-LMP2-3B was able to eliminate the high-titer serum antibody response in BALB/c mice. Western blot analysis and indirect immunofluorescence assay confirmed that the mouse immune sera recognized the native LMP2. Compared with healthy adults, patients with NPC demonstrated significantly greater reactivity to EBV-LMP2-3B (P<0.05). Furthermore, it was possible to effectively detect specific IgG in sera from patients with NPC, with a sensitivity of 91.91% and specificity of 93.14%, representing an improvement over the traditional viral capsid antigen-IgA-based detection method with 59.59% sensitivity and 75.49% specificity. In conclusion, the EBV-LMP2-3B protein may be used as a serological diagnostic reagent to screen for and diagnose NPC.
资助项目	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81372447]
出版者	SPANDIDOS PUBL LTD
出版地	ATHENS
ISSN	1792-1074
EISSN	1792-1082
卷号	16 期号:4 页码:4372-4378
DOI	10.3892/ol.2018.9216
页数	7
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:000444990700037
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	30214572
PMC记录号	PMC6126329
SCOPUSEID	2-s2.0-85052364681
通讯作者地址	[Zhu, Guanbao]Department of General Surgery,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,325000,China
Scopus学科分类	Oncology;Cancer Research
引用统计	被引频次：5[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/12640
专题	附属第一医院基础医学院（机能实验教学中心）_病原生物学与免疫学系
通讯作者	Zhu, Guanbao
作者单位	1.Department of General Surgery,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,325000,China; 2.Institute of Molecular Virology and Immunology,Department of Medical Microbiology and Immunology,Wenzhou Medical University,Wenzhou,325000,China
第一作者单位	附属第一医院; 第一临床医学院（信息与工程学院）、附属第一医院
通讯作者单位	附属第一医院; 第一临床医学院（信息与工程学院）、附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Cai, Yiqi,Song, Yiling,Cen, Danwei,et al. Novel ELISA for serodiagnosis of nasopharyngeal carcinoma based on a B cell epitope of Epstein-Barr virus latent membrane protein 2[J]. ONCOLOGY LETTERS,2018,16(4):4372-4378.
APA	Cai, Yiqi., Song, Yiling., Cen, Danwei., Zhang, Chanqiong., Mao, Shanshan., ... & Zhu, Guanbao. (2018). Novel ELISA for serodiagnosis of nasopharyngeal carcinoma based on a B cell epitope of Epstein-Barr virus latent membrane protein 2. ONCOLOGY LETTERS, 16(4), 4372-4378.
MLA	Cai, Yiqi,et al."Novel ELISA for serodiagnosis of nasopharyngeal carcinoma based on a B cell epitope of Epstein-Barr virus latent membrane protein 2".ONCOLOGY LETTERS 16.4(2018):4372-4378.